- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00902915
Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure
November 21, 2013 updated by: Austrian Forum Against Cancer
The purpose of this study is to determine efficacy of lenalidomide and dexamethasone in the treatment of patients with acute Myeloma (light chain)-induced renal failure.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Salzburg, Austria, 5020
- LKH Salzburg, 3rd Med. Dept.
-
Vienna, Austria, 1160
- Austrian Forum Against Cancer; 1st Med. Dept., Center for Hematology and Oncology, Wilhelminenspital, Montleartstrasse 37
-
Wels, Austria, 4600
- Clinic Wels-Grieskirchen, 4th Internal Dept.
-
-
-
-
-
Brno, Czech Republic, 62500
- Faculty Hospital Brno and Faculty of Medicine MU
-
Prague, Czech Republic, 12821
- Charles University Prague
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Understand and voluntarily sign an informed consent form.
- Age at least 18 years at the time of signing the informed consent form.
- MM (all stages) with acute light chain induced renal impairment
- Patients with previously unknown MM and acute light chain induced renal failure (GFR<50ml/min and serum creatinine minimum 2.0 mg/dL) and with further workup revealing light chain induced renal injury with MM as underlying cause.
- Patients with previously established MM and normal renal function (GFR ≥60ml/min and serum creatinine ≤1.2mg/dl) with progressive disease and acute (within 6 weeks) light chain induced renal failure (GFR<50ml/min and creatinine ≥ 2.0 mg/dL).
Disease progression will be documented by one or more of the following criteria:
- Increase in serum paraprotein by >25%, or increase of 50% of 24 hour urine paraprotein excretion
- Hypercalcemia
- Progression of bone lesions
- Decrease in Hb>2g/dl within 4 weeks (not induced by cytotoxic drugs)
- Increase in bone marrow plasma cell infiltration by > 25%
- All previous medical anti-myeloma therapy (excluding corticosteroids) must have been discontinued at least 3 weeks prior to treatment in this study.
- Able to adhere to the study visit schedule and other protocol requirements.
- Measurable serum or urine paraprotein
Laboratory test results within these ranges:
- Glomerular filtration rate < 50ml/min
- Serum creatinine ≥ 2.0mg/dL
- Absolute leukocyte count ≥ 1.5 x 10G/L
- Platelet count minimum 75 x 10G/L if bone marrow plasma cell infiltration (BMPC) is ≥50% or minimum 30 x 10G/L if BMPC infiltration is <50%.
- Total bilirubin minimum 1.5 mg/dL
- AST (SGOT) and ALT (SGPT) not more than 2,5 x ULN
Females of childbearing potential (FCBP) must:
- Understand that the study medication could have an expected teratogenic risk
- Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception: Implant, Levonorgestrel-releasing intrauterine system (IUS, Medroxyprogesterone acetate depot), Tubal sterilization, Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses Ovulation inhibitory progesterone-only pills (i.e., desogestrel)
- Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml not more than 3 days before the start of study medication once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
- Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These tests should be performed not more than 3 days before the start of next treatment. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
Male subjects must:
- Agree to use condoms throughout study drug therapy, during any dose interruption and for 28 days after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- Agree not to donate semen during study drug therapy and for 28 days after end of study drug therapy.
- All subjects must agree not to share study medication with another person and to return all unused study drug to the investigator
- Disease free of prior malignancies for minimum of 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast
- Agree to take low molecular weight heparin as prophylactic anticoagulation.
Exclusion Criteria:
- Acute renal failure due to other causes than light-chain induced nephropathy such as NSAIRS, antibiotics, or other nephrotoxic drugs, or others.
- Acute renal failure due to hypercalcemia only, without excretion of nephrotoxic light chains.
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Any prior use of lenalidomide
- Any anti-myeloma therapy within 3 weeks before day 1 of first cycle, with the exception of dexamethasone 40mg (maximum dose 160mg) or corticosteroid equivalent.
- Any other experimental drug or therapy within 3 weeks of baseline
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Known positive for HIV or infectious hepatitis, type A, B or C or evidence of any severe active or chronic infection.
- Clinical significant heart disease (NYHA status>2)
- Pregnant or breast feeding females
- Anamnesis of thromboembolic complications, such as stroke, myocardial infarction and pulmonary embolism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lenalidomide - Dexamethasone
|
peroral application; lenalidomide dosage according to severity grade of renal failure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the response rate (CR, VGPR, PR, MR, SD, and PD) To determine the renal response rate To determine the relation between category of myeloma response and improvement in GFR To determine the proportion of patients spared hemodialysis
|
Secondary Outcome Measures
Outcome Measure |
---|
Progression Free Survival, Event Free Survival, Overall Survival; Toxicity, evaluated according to the NCCN toxicity scale (type, frequency, severity, and relationship of adverse events to study treatment).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Anticipated)
May 1, 2014
Study Completion (Anticipated)
May 1, 2014
Study Registration Dates
First Submitted
May 14, 2009
First Submitted That Met QC Criteria
May 14, 2009
First Posted (Estimate)
May 15, 2009
Study Record Updates
Last Update Posted (Estimate)
November 25, 2013
Last Update Submitted That Met QC Criteria
November 21, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Kidney Diseases
- Urologic Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Renal Insufficiency
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Lenalidomide
Other Study ID Numbers
- LD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma Light Chain Induced Renal Insufficiency
-
SanofiRecruitingRelapsed/Refractory Multiple Myeloma | Amyloid Light-chain AmyloidosisItaly, Australia, Belgium, Hungary, Spain, United Kingdom, Czechia
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.CompletedAmyloidosis | Light Chain Deposition Disease (LCDD or MIDD) | Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | Monoclonal Immunoglobulin Deposition Disease (MIDD)United States
-
Margarida Magalhaes-SilvermanNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Primary Systemic Amyloidosis | Light Chain Deposition Disease | Extramedullary Plasmacytoma | Isolated Plasmacytoma of BoneUnited States
-
IRCCS Policlinico S. MatteoWithdrawnPrimary Amyloidosis of Light Chain TypeItaly
-
TakedaCompletedMultiple Myeloma | Immunoglobulin Light-chain AmyloidosisSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain OnlyUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Light Chain Deposition DiseaseUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedPrimary Systemic Amyloidosis | Light Chain Deposition DiseaseUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)TerminatedPrimary Systemic Amyloidosis | Light Chain Deposition DiseaseUnited States, Canada
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAmyloidosis | Plasma Cell MyelomaUnited States
Clinical Trials on lenalidomide plus dexamethasone
-
CelgeneCompletedMultiple MyelomaSpain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
-
University of LeedsTakeda; Cancer Research UK; CelgeneRecruitingMultiple MyelomaUnited Kingdom
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Institut de Cancérologie de la LoireCelgene CorporationCompletedLeukemia, Lymphoid | Precursor B-Cell Lymphoblastic Leukemia-LymphomaFrance
-
Bristol-Myers SquibbCompletedMultiple MyelomaUnited States, France, Australia
-
University of Michigan Rogel Cancer CenterCelgene; Onyx Therapeutics, Inc.CompletedMultiple MyelomaUnited States
-
University of LeedsMerck Sharp & Dohme LLC; Celgene; AmgenUnknown
-
Gesellschaft fur Medizinische Innovation - Hamatologie...ClinAssess GmbHCompletedMultiple MyelomaGermany
-
European Myeloma NetworkSanofi; Amgen; EMN Research ItalyActive, not recruitingMultiple MyelomaCzechia, Germany, Greece, Italy, Netherlands, Norway, Spain
-
University Health Network, TorontoCompletedMultiple Myeloma | Renal FailureCanada